was read the article
array:23 [ "pii" => "S2531043718301570" "issn" => "25310437" "doi" => "10.1016/j.pulmoe.2018.10.003" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1318" "copyright" => "Sociedade Portuguesa de Pneumologia" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Pulmonol. 2018;24:361-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1977 "formatos" => array:3 [ "EPUB" => 193 "HTML" => 1099 "PDF" => 685 ] ] "itemAnterior" => array:19 [ "pii" => "S2531043718301557" "issn" => "25310437" "doi" => "10.1016/j.pulmoe.2018.09.007" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1317" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Pulmonol. 2018;24:357-60" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1355 "formatos" => array:3 [ "EPUB" => 208 "HTML" => 676 "PDF" => 471 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Research letter</span>" "titulo" => "Understanding symptoms variability in outpatients with AECOPD" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "357" "paginaFinal" => "360" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1652 "Ancho" => 2083 "Tamanyo" => 126072 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Correlations between changes from T1 to T3 in A) modified Borg scale – dyspnoea (MBS.d) and forced expiratory volume in 1 second (FEV1); B) modified Borg scale – fatigue (MBS.f) and FEV1; C) modified British Medical Research Council questionnaire (mMRC) and quadriceps muscle strength (QMS); D) Cough, assessed with the numerical scale, and QMS.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Oliveira, Alda Marques" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ana" "apellidos" => "Oliveira" ] 1 => array:2 [ "nombre" => "Alda" "apellidos" => "Marques" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2531043718301557?idApp=UINPBA00004E" "url" => "/25310437/0000002400000006/v2_201902120618/S2531043718301557/v2_201902120618/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Reversible diffuse lung disease after mycophenolate mofetil withdrawal" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "361" "paginaFinal" => "362" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Romina Abelleira, María Elena Toubes, Juan Suárez-Antelo, Luis Valdés" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Romina" "apellidos" => "Abelleira" "email" => array:1 [ 0 => "romina.abelleira.paris@sergas.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "María" "apellidos" => "Elena Toubes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Juan" "apellidos" => "Suárez-Antelo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Luis" "apellidos" => "Valdés" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Pneumology Department, Hospital Clínico Universitario, Santiago de Compostela, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Interdisciplinary Pneumology Research Group, Santiago de Compostela Health Research Institutions (IDIS), Santiago de Compostela, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2310 "Ancho" => 1500 "Tamanyo" => 488802 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A Multiple small consolidations in both lungs with areas of ground glass opacification and small bilateral pleural effusion of left predominance. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B. Complete resolution of the extensive pulmonary disease with consolidative component and ground glass, as well as the small bilateral pleural effusion.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Mycophenolate mofetil (MMF) is a cell cycle inhibitor widely used in patients with solid organ transplants<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>, in the treatment of many autoimmune diseases<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> and, even, in hypersensitivity pneumonitis<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>. Its most frequent side effects are myelosuppression, gastrointestinal disorders and an increased susceptibility to infections, including pneumonia<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a>. The development of interstitial lung disease after taking this drug is a rare adverse effect of which only isolated cases have been published<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5–7</span></a>. We present a patient with pulmonary toxicity due to MMF.</p><p id="par0010" class="elsevierStylePara elsevierViewall">A 72-year-old woman came to the Emergency Department after seven days of fever, asthenia and dyspnoea. In 2008, she had received a kidney transplant due to chronic renal failure secondary to Polycystic kidney disease and had begun treatment with corticosteroids, sirolimus and MMF (640<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>hours). In 2014, a chest computed tomography (CT) scan revealed an extended micronodular interstitial lung disease that disappeared after withdrawal of sirolimus. It was interpreted as a pulmonary toxicity and was replaced by tacrolimus.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Upon arrival to the Emergency Room she had a fever (37.5<span class="elsevierStyleHsp" style=""></span>°C) with diminished respiratory sounds and crackles in the middle of the left hemithorax. The patient had never smoked, had no close contact with animals and had not engaged in any potentially harmful professional, recreational or domestic activities. Blood test results showed hemoglobin 11.7<span class="elsevierStyleHsp" style=""></span>g/dL, leukocytes 5,000/mm<span class="elsevierStyleSup">3</span> with lymphopenia (650/mm<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>; 13%), urea 70<span class="elsevierStyleHsp" style=""></span>mg/dL, creatinine 1.57<span class="elsevierStyleHsp" style=""></span>mg/dL and C-reactive protein 1.9<span class="elsevierStyleHsp" style=""></span>mg/dL. Arterial blood gases evidenced hypoxemia (pO2 49.7<span class="elsevierStyleHsp" style=""></span>mmHg) and chest CT demonstrated multifocal pulmonary lesions with areas of ground-glass and small bilateral pleural effusion of left predominance (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A). The cultures in different biological samples (blood, sputum, bronchoalveolar lavage and pleural fluid) for bacteria, tuberculosis, virus (cytomegalovirus, influenza, parainfluenza, herpes, chickenpox, syncytial, HIV, etc.), aspergillus-galactomannan and <span class="elsevierStyleItalic">pneumocystis jirovecii</span> were all negatives. Serology against Coxiella, Legionella, Chlamydia, Toxoplasma and Mycoplasma pneumoniae was negative. Macroscopically, bronchofibroscopy was normal. Bronchoalveolar lavage showed a lymphocyte predominance (50%) with a CD4/CD8 T-lymphocyte ratio of 4.35. There were relevant alterations in the smear findings. The pleural fluid had biochemical exudate characteristics with 100% mononuclear cells and an adenosine deaminase of 14 IU/L. Echocardiography ruled out endocarditis. Neither pulmonary function tests nor any type of lung biopsy were performed due to the patient's clinical situation and the presumably limited collaboration. During the first days of admission, treatment with MMF and tacrolimus were maintained, and different antibiotic cycles were performed (levofloxacin, ceftriaxone, piperacillin/tazobactam, voriconazole, amikacin and linezolid), without improvement. The fact that all cultures were negative and the lack of response obtained led to rejection of the hypothesis of an infectious cause in an immunocompromised patient and to considering the possibility of pulmonary toxicity. Antibiotics and MMF were discontinued and tacrolimus was maintained. Since then, the clinical and radiological improvement was progressive, with resolution of fever, respiratory failure and radiological alterations, including pleural effusion (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B). Once clinical improvement was observed, the oral corticosteroid dose of methylprednisolone was increased to 80<span class="elsevierStyleHsp" style=""></span>mg/day. After nine months of follow-up, the patient is asymptomatic.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">MMF is used as a first or second immunosuppressant line in solid organ transplant protocols since it inhibits the purine biosynthesis of T and B lymphocytes through the inosine monophosphate dehydrogenase enzyme, limiting the proliferation of lymphocytes. In this way, there is a reduction in the generation of effector lymphocytes for T cell-mediated immunity and the production of antibodies. Its profile of adverse effects is acceptable. In all cases published to date, the appearance of interstitial lung disease induced by MMF manifested in the short-medium term (maximum 18 months) after the introduction of the drug<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a>. However, this is the first case described in which lung disease appears after the use of MMF in the long term (9 years).</p><p id="par0025" class="elsevierStylePara elsevierViewall">The development of interstitial lung disease with MMF is an unusual side effect of immunosuppression. The main difficulty in establishing a link between any immunosuppressive agent and a lung disease is that it is a diagnosis of exclusion. In this case, the temporal relationship, the clinical and CT characteristics of the thorax, the negative cultures and the symptomatic and radiological improvement after the removal of MMF suggest interstitial lung disease induced by MMF, although an atypical infection cannot be safely excluded. Cryptogenetic organizing pneumonia and pulmonary eosinophilia were ruled out when presenting clinical-radiological improvement with a minimum dose of corticosteroids and eosinophils were not demonstrated in bronchoalveolar lavage, respectively.</p><p id="par0030" class="elsevierStylePara elsevierViewall">In summary, what can be learned from this case is that MMF is a drug that must be taken into account as a potential cause of interstitial lung disease. Although rare, this is a serious adverse effect. Therefore, in the presence of fever, dyspnoea and diffuse pulmonary involvement in chest CT, this possibility should be considered. An empirical test of MMF suspension and observation of symptomatic improvement could be enough to identify the drug as the probable cause of the disease.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "abr" "titulo" => "Abbreviations" "identificador" => "xpalclavsec1077803" "palabras" => array:2 [ 0 => "CT" 1 => "MMF" ] ] ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2310 "Ancho" => 1500 "Tamanyo" => 488802 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A Multiple small consolidations in both lungs with areas of ground glass opacification and small bilateral pleural effusion of left predominance. <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B. Complete resolution of the extensive pulmonary disease with consolidative component and ground glass, as well as the small bilateral pleural effusion.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.E. Staatz" 1 => "S.E. Tett" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00204-014-1247-1" "Revista" => array:6 [ "tituloSerie" => "Arch Toxicol" "fecha" => "2014" "volumen" => "88" "paginaInicial" => "1351" "paginaFinal" => "1389" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24792322" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American college of rheumatology guidelines for screening, treatment and management of lupus nephritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B.H. Hahn" 1 => "M.A. McMahon" 2 => "A. Wilkinson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Arthritis Care Res" "fecha" => "2012" "volumen" => "64" "paginaInicial" => "797" "paginaFinal" => "808" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.P. Tashkin" 1 => "M.D. Roth" 2 => "P.J. Clements" 3 => "D.E. Furst" 4 => "D. Khanna" 5 => "E.C. Kleerup" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2016" "volumen" => "4" "paginaInicial" => "708" "paginaFinal" => "719" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Morriset" 1 => "K.A. Johannson" 2 => "E. Vittinghoff" 3 => "C. Aravena" 4 => "B.M. Elicker" 5 => "K.D. Jones" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Chest" "fecha" => "2017" "volumen" => "151" "paginaInicial" => "619" "paginaFinal" => "625" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.C. Gross" 1 => "T.M. Sasaki" 2 => "M.K. Buick" 3 => "J.A. Light" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Transplantation" "fecha" => "1997" "volumen" => "64" "paginaInicial" => "1607" "paginaFinal" => "1609" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reversible chronic pulmonary fibrosis associated with MMF in a pediatric patient: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B.C. Reynolds" 1 => "J.Y. Paton" 2 => "A.G. Howatson" 3 => "I.J. Ramage" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pediatr Transplant" "fecha" => "2008" "volumen" => "12" "paginaInicial" => "228" "paginaFinal" => "231" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reversible interstitial lung disease following treatment of atopic dermatitis with mycophenolate mofetil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T.J. Tull" 1 => "TomaT" 2 => "H.P. Menagé" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2016" "volumen" => "41" "paginaInicial" => "702" "paginaFinal" => "703" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25310437/0000002400000006/v2_201902120618/S2531043718301570/v2_201902120618/en/main.assets" "Apartado" => array:4 [ "identificador" => "72880" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25310437/0000002400000006/v2_201902120618/S2531043718301570/v2_201902120618/en/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2531043718301570?idApp=UINPBA00004E" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 24 | 5 | 29 |
2024 October | 197 | 41 | 238 |
2024 September | 184 | 53 | 237 |
2024 August | 195 | 72 | 267 |
2024 July | 238 | 62 | 300 |
2024 June | 191 | 64 | 255 |
2024 May | 183 | 79 | 262 |
2024 April | 221 | 52 | 273 |
2024 March | 188 | 45 | 233 |
2024 February | 159 | 43 | 202 |
2024 January | 170 | 31 | 201 |
2023 December | 113 | 36 | 149 |
2023 November | 118 | 64 | 182 |
2023 October | 124 | 54 | 178 |
2023 September | 102 | 55 | 157 |
2023 August | 121 | 34 | 155 |
2023 July | 137 | 46 | 183 |
2023 June | 94 | 24 | 118 |
2023 May | 131 | 37 | 168 |
2023 April | 97 | 26 | 123 |
2023 March | 111 | 41 | 152 |
2023 February | 100 | 39 | 139 |
2023 January | 91 | 28 | 119 |
2022 December | 118 | 23 | 141 |
2022 November | 135 | 40 | 175 |
2022 October | 145 | 57 | 202 |
2022 September | 94 | 36 | 130 |
2022 August | 107 | 45 | 152 |
2022 July | 120 | 48 | 168 |
2022 June | 88 | 34 | 122 |
2022 May | 103 | 43 | 146 |
2022 April | 69 | 39 | 108 |
2022 March | 103 | 55 | 158 |
2022 February | 75 | 36 | 111 |
2022 January | 99 | 55 | 154 |
2021 December | 72 | 44 | 116 |
2021 November | 85 | 44 | 129 |
2021 October | 167 | 63 | 230 |
2021 September | 106 | 43 | 149 |
2021 August | 103 | 42 | 145 |
2021 July | 105 | 21 | 126 |
2021 June | 144 | 26 | 170 |
2021 May | 209 | 56 | 265 |
2021 April | 410 | 119 | 529 |
2021 March | 260 | 54 | 314 |
2021 February | 162 | 43 | 205 |
2021 January | 174 | 37 | 211 |
2020 December | 147 | 38 | 185 |
2020 November | 109 | 33 | 142 |
2020 October | 109 | 45 | 154 |
2020 September | 113 | 42 | 155 |
2020 August | 133 | 34 | 167 |
2020 July | 124 | 39 | 163 |
2020 June | 129 | 31 | 160 |
2020 May | 134 | 34 | 168 |
2020 April | 128 | 28 | 156 |
2020 March | 138 | 36 | 174 |
2020 February | 148 | 29 | 177 |
2020 January | 109 | 46 | 155 |
2019 December | 82 | 57 | 139 |
2019 November | 71 | 26 | 97 |
2019 October | 86 | 37 | 123 |
2019 September | 83 | 43 | 126 |
2019 August | 67 | 35 | 102 |
2019 July | 75 | 38 | 113 |
2019 June | 62 | 34 | 96 |
2019 May | 46 | 51 | 97 |
2019 April | 63 | 55 | 118 |
2019 March | 62 | 50 | 112 |
2019 February | 90 | 76 | 166 |
2019 January | 95 | 79 | 174 |
2018 December | 31 | 39 | 70 |